KR102237356B1 - 지연 방출 약물 제형 - Google Patents

지연 방출 약물 제형 Download PDF

Info

Publication number
KR102237356B1
KR102237356B1 KR1020207017564A KR20207017564A KR102237356B1 KR 102237356 B1 KR102237356 B1 KR 102237356B1 KR 1020207017564 A KR1020207017564 A KR 1020207017564A KR 20207017564 A KR20207017564 A KR 20207017564A KR 102237356 B1 KR102237356 B1 KR 102237356B1
Authority
KR
South Korea
Prior art keywords
drug
coating
layer
polymeric material
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207017564A
Other languages
English (en)
Korean (ko)
Other versions
KR20200075041A (ko
Inventor
펠리페 요세 올리베이라 바룸
곤잘레스 로베르토 카를로스 브라보
토마스 부세르
아브덜 와세 바싯
애나 크리스티나 프레이레
Original Assignee
틸로츠 파마 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 틸로츠 파마 아게 filed Critical 틸로츠 파마 아게
Publication of KR20200075041A publication Critical patent/KR20200075041A/ko
Application granted granted Critical
Publication of KR102237356B1 publication Critical patent/KR102237356B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207017564A 2013-10-29 2013-10-29 지연 방출 약물 제형 Active KR102237356B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/072648 WO2015062640A1 (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167007738A Division KR102174942B1 (ko) 2013-10-29 2013-10-29 지연 방출 약물 제형

Publications (2)

Publication Number Publication Date
KR20200075041A KR20200075041A (ko) 2020-06-25
KR102237356B1 true KR102237356B1 (ko) 2021-04-08

Family

ID=49515360

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207017564A Active KR102237356B1 (ko) 2013-10-29 2013-10-29 지연 방출 약물 제형
KR1020167007738A Active KR102174942B1 (ko) 2013-10-29 2013-10-29 지연 방출 약물 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167007738A Active KR102174942B1 (ko) 2013-10-29 2013-10-29 지연 방출 약물 제형

Country Status (25)

Country Link
US (1) US10799515B2 (https=)
EP (2) EP3542791A1 (https=)
JP (1) JP6273356B2 (https=)
KR (2) KR102237356B1 (https=)
CN (2) CN110279669B (https=)
AU (2) AU2013404367B2 (https=)
BR (2) BR122020013726B1 (https=)
CA (1) CA2923063C (https=)
CR (1) CR20160192A (https=)
CU (1) CU20160055A7 (https=)
EA (1) EA032504B1 (https=)
HK (1) HK1222547A1 (https=)
IL (2) IL244260B (https=)
MA (1) MA38847B2 (https=)
MX (2) MX382146B (https=)
MY (1) MY189394A (https=)
NZ (2) NZ717159A (https=)
PH (2) PH12020551522A1 (https=)
SA (2) SA114360006B1 (https=)
SG (1) SG11201600501UA (https=)
TN (1) TN2016000119A1 (https=)
TW (3) TWI736031B (https=)
UA (1) UA117260C2 (https=)
WO (1) WO2015062640A1 (https=)
ZA (1) ZA201600630B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2659881T3 (pl) 2012-04-30 2018-05-30 Tillotts Pharma Ag Formulacja leku o opóźnionym uwalnianiu
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
CA3085223A1 (en) * 2017-12-21 2019-06-27 Pepsico, Inc. Multi-ingredient ephemeral beverage pod for making a beverage
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
ES3002632T3 (en) 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
KR20220113698A (ko) * 2019-12-11 2022-08-16 에보닉 오퍼레이션스 게엠베하 질환을 치료 또는 예방하는데 사용하기 위한 투여 형태

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192282A1 (en) 2000-03-17 2002-12-19 Thomas Beckert Multilayer pharmaceutical product for release in the colon
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
WO2008135090A1 (en) * 2007-05-07 2008-11-13 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
JP2008543929A (ja) * 2005-06-20 2008-12-04 カディラ・ヘルスケア・リミテッド デュロキセチンの調節放出型の投与製剤
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20090175935A1 (en) 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
JP2012153724A (ja) 2005-05-02 2012-08-16 Aptalis Pharmatech Inc 時限パルス放出システム

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) * 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CA2236605A1 (en) 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ATE238797T1 (de) 1999-12-16 2003-05-15 Medinfar Produtos Farmaceutico Piroxicam enthaltende gastrointestinale zubereitung aus merheren einheiten bestehend
FI20000780A7 (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
WO2002096405A1 (en) * 2001-05-25 2002-12-05 Ssp Co., Ltd. Drug preparations
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
JP2006515318A (ja) 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
AU2002361495A1 (en) 2002-12-24 2004-07-22 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
US20100209520A1 (en) 2007-03-26 2010-08-19 Hiroyuki Kubo Oral pharmaceutical preparation for colon-specific delivery
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP2384746A3 (en) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130259947A1 (en) 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
AU2012305915B2 (en) 2011-09-07 2017-09-07 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal
CN102319218B (zh) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
PL2659881T3 (pl) 2012-04-30 2018-05-30 Tillotts Pharma Ag Formulacja leku o opóźnionym uwalnianiu
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192282A1 (en) 2000-03-17 2002-12-19 Thomas Beckert Multilayer pharmaceutical product for release in the colon
JP2012153724A (ja) 2005-05-02 2012-08-16 Aptalis Pharmatech Inc 時限パルス放出システム
JP2008543929A (ja) * 2005-06-20 2008-12-04 カディラ・ヘルスケア・リミテッド デュロキセチンの調節放出型の投与製剤
US20090175935A1 (en) 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
WO2008135090A1 (en) * 2007-05-07 2008-11-13 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet

Also Published As

Publication number Publication date
SA114360006B1 (ar) 2016-11-09
CN110279669B (zh) 2022-02-15
TWI725458B (zh) 2021-04-21
NZ717159A (en) 2019-06-28
CA2923063C (en) 2021-09-07
SA116370660B1 (ar) 2019-02-24
MX2016001840A (es) 2016-08-11
ZA201600630B (en) 2017-05-31
BR112016004863A8 (pt) 2020-02-11
TW202011945A (zh) 2020-04-01
CR20160192A (es) 2016-07-13
MX382146B (es) 2025-03-13
US20160250232A1 (en) 2016-09-01
SG11201600501UA (en) 2016-02-26
TWI736031B (zh) 2021-08-11
JP2016535030A (ja) 2016-11-10
TWI680774B (zh) 2020-01-01
IL265381B (en) 2022-05-01
EA201690596A1 (ru) 2016-08-31
CN105555260A (zh) 2016-05-04
EP3062776A1 (en) 2016-09-07
EP3542791A1 (en) 2019-09-25
KR102174942B1 (ko) 2020-11-06
PH12016500307B1 (en) 2022-02-11
PH12020551522A1 (en) 2022-11-14
CU20160055A7 (es) 2016-10-28
JP6273356B2 (ja) 2018-01-31
AU2013404367A1 (en) 2016-02-18
US10799515B2 (en) 2020-10-13
AU2020201365A1 (en) 2020-03-12
UA117260C2 (uk) 2018-07-10
BR122020013726B1 (pt) 2022-11-01
MY189394A (en) 2022-02-09
TW201542243A (zh) 2015-11-16
NZ747731A (en) 2020-02-28
EA032504B1 (ru) 2019-06-28
WO2015062640A1 (en) 2015-05-07
CA2923063A1 (en) 2015-05-07
KR20200075041A (ko) 2020-06-25
CN110279669A (zh) 2019-09-27
AU2013404367B2 (en) 2020-02-27
MA38847B2 (fr) 2021-02-26
BR112016004863B1 (pt) 2022-09-20
IL244260B (en) 2021-08-31
MX2019002162A (es) 2019-06-17
AU2020201365B2 (en) 2021-09-16
PH12016500307A1 (en) 2016-05-16
IL265381A (en) 2019-05-30
TN2016000119A1 (en) 2017-10-06
TW201944984A (zh) 2019-12-01
KR20160077040A (ko) 2016-07-01
HK1222547A1 (zh) 2017-07-07
MA38847A1 (fr) 2017-08-31
MX388063B (es) 2025-03-19
IL244260A0 (en) 2016-04-21
CN105555260B (zh) 2021-04-23

Similar Documents

Publication Publication Date Title
US11534406B2 (en) Delayed release drug formulation
AU2020201365B2 (en) A delayed release drug formulation
JP2017145268A (ja) 遅延放出性薬物製剤
HK40011020A (en) A delayed release drug formulation
HK1240817A (en) A delayed release drug formulation

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6